Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR)

• Novocure recently announced that final results from the pivotal Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small cell lung cancer (NSCLC) were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting and published simultaneously in a leading clinical journal.
• This milestone provides critical new data on TTFields therapy in a significant and challenging cancer indication, highlighting progress in expanding the clinical utility of Novocure’s technology.
• We will examine how the METIS trial’s final results influence Novocure’s investment narrative, especially in the context of potential new indications.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

NovoCure Investment Narrative Recap

At the heart of the NovoCure investment case is belief in Tumor Treating Fields (TTFields) driving market expansion into new cancer indications, with regulatory and clinical milestones as short-term catalysts. The recent presentation and publication of final Phase 3 METIS trial results for TTFields in NSCLC brain metastases may help support this narrative, yet the key near-term risk, predictable revenue growth, given ongoing reimbursement and adoption challenges, remains largely unchanged by these clinical data alone.

NovoCure’s September 15, 2025, approval in Japan for Optune Lua® with PD-1/PD-L1 inhibitors in advanced/recurrent NSCLC directly ties to TTFields’ expansion ambitions, reinforcing progress in new market access regions and potentially complementing the significance of METIS trial results as a future growth driver.

In contrast, reimbursement hurdles and the unpredictability of coverage decisions worldwide remain key issues that investors should be aware of...

Read the full narrative on NovoCure (it's free!)

NovoCure's outlook anticipates $863.5 million in revenue and $107.8 million in earnings by 2028. This projection assumes an 11.1% annual revenue growth rate and a $278.8 million increase in earnings from current earnings of -$171.0 million.

Uncover how NovoCure's forecasts yield a $27.19 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided three fair value estimates for NovoCure, with individual targets ranging widely from US$27.19 to US$66.29. Amidst these varied perspectives, uncertainty around broad reimbursement and revenue predictability continues to be a central concern affecting future performance.

Explore 3 other fair value estimates on NovoCure - why the stock might be worth over 4x more than the current price!

Build Your Own NovoCure Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NovoCure research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free NovoCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NovoCure's overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 35 companies in the world exploring or producing it. Find the list for free.
• We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com